Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation (NASDAQ:AMRN) announced a requisition by Sarissa Capital Management to convene a Special Meeting of Shareholders. The Company reported significant operational progress and a 70% refreshment of its Board of Directors, enhancing expertise in finance and global commercialization. Positive developments include successful pricing and reimbursement strategies in Europe, stabilization in the U.S. market, and improved cash flow of $4 million in Q4 2022. Amarin is focused on achieving $100 million in cost reductions by mid-2023. A proxy contest with Sarissa may disrupt ongoing strategic efforts.
Sarissa Capital Management is calling for drastic changes to the Amarin Corporation board, citing a lack of credibility and responsiveness to shareholder concerns. Following a shareholder meeting where mistrust towards the board was evident, Sarissa expressed disappointment that their nominee suggestions were ignored. The board's recent acknowledgment of the need for refreshment is seen as insufficient. Sarissa is pursuing a special meeting to add seven directors and remove Chairman Per Wold-Olsen. They warn of legal action if their shareholder rights are obstructed.
Amarin Corporation plc (NASDAQ:AMRN) reported a preliminary revenue of $88-$90 million for Q4 2022, totaling $367-$369 million for the full year, marking the fourth consecutive quarter of revenue stabilization in the U.S. Cash reserves stand at approximately $310 million, with a positive cash flow of $4 million in Q4. The company continues to make progress in European markets, securing positive reimbursement decisions in five countries and pursuing negotiations in others. The CEO emphasized a focus on growth and adaptation to market conditions.
Amarin Corporation plc (NASDAQ:AMRN) has appointed Dr. Murray W. Stewart to its Board of Directors, following a significant board refreshment initiative that has resulted in around 70% new independent directors within the past year. Dr. Stewart brings over 30 years of cardiometabolic academic and industry experience, including roles at GlaxoSmithKline and Rhythm Pharmaceuticals. His appointment aligns with Amarin's strategy to expand into Europe and diversify its product portfolio, enhancing its focus on global, cardiometabolic health.
Amarin Corporation plc (NASDAQ:AMRN) announced that CEO Karim Mikhail will speak at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 8:15 p.m. ET. This event occurs from January 9-12, 2023, in San Francisco, California. The presentation will be webcast live and available for later viewing on Amarin's Investor Relations webpage.
Amarin focuses on cardiovascular disease management, emphasizing scientific research and clinical trials as it expands its commercial presence.
Amarin Corporation plc (NASDAQ:AMRN) announced the approval of its drug VAZKEPA (icosapent ethyl) by Switzerland's Swissmedic. The drug is indicated for reducing cardiovascular risks in high-risk adults. This marks the sixth approval of the VAZKEPA franchise in 2022. Amarin is concurrently pursuing national pricing and reimbursement, expected to complete in 2023. The approval supports Amarin's strategy to strengthen its European operations, having established a regional hub in Zug, Switzerland, in 2021, which hosts over 30 employees dedicated to commercial and medical roles.
Amarin Corporation announced that Australia's Therapeutic Goods Administration (TGA) has approved VAZKEPA (icosapent ethyl) for reducing the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk and elevated triglycerides. This marks the fifth regulatory approval for the VAZKEPA franchise in key international markets in 2022. The company will initiate the reimbursement process to support commercialization in Australia, backed by patents providing market exclusivity into the early 2030s.
Amarin Corporation (NASDAQ:AMRN) announced that CEO Karim Mikhail will participate in the Jefferies London Healthcare Conference from November 15-17, 2022. Mikhail's presentation is scheduled for November 16, 2022, at 9:40 a.m. ET (2:40 p.m. GMT+1).
This event will be webcast live, with an archived version available on Amarin's Investor Relations website. The company focuses on advancing cardiovascular disease management through scientific research and clinical trials.
Amarin Corporation presents key findings from the RESPECT-EPA study at the AHA 2022 Scientific Sessions, highlighting the cardiovascular risk reduction benefits of eicosapentaenoic acid (EPA) for patients with coronary artery disease (CAD). The study demonstrated a 21.5% reduction in cardiovascular risk (p=0.054) and a 26.6% reduction in a secondary endpoint (p=0.03). In contrast, the PROMINENT study reported no cardiovascular benefits from the fibrate class for high-risk patients. The results reinforce the therapeutic value of VASCEPA/VAZKEPA in managing cardiovascular risk alongside statin therapy.
Amarin Corporation (NASDAQ:AMRN) announced Q3 2022 financial results, reporting a net revenue of $89.9 million, down 37% from Q3 2021, largely due to increasing generic competition affecting VASCEPA sales. The company secured positive reimbursement assessments in several European markets, including Finland and the Netherlands, and launched VAZKEPA in the UK. Efforts to stabilize US revenues continued, achieving a cash-positive quarter excluding restructuring charges. Amarin's cost-saving measures are projected to yield $100 million by mid-2023, extending its cash runway amid ongoing market access negotiations.